SCHEMBL566735

SCHEMBL566735

O=C1/C(=C/O)SCc2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 1/20 0.53
▸ CES1 P23141 2/20 0.44
▸ MAOA P21397 2/20 0.44
▸ AKR1B1 P15121 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ S100A4 P26447 1/20 0.41
▸ BCHE P06276 1/20 0.41
▸ MAPK14 Q16539 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ MIF P14174 5/20 0.38
▸ MAOB P27338 2/20 0.38
▸ JAK2 O60674 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL566736 1.00 ACHE (0.53) ACHECES1MAOAAKR1B1ALDH1A1
SCHEMBL565749 0.82 ACHE (0.53) ACHECES1MAOAAKR1B1ALDH1A1
SCHEMBL567340 0.82 ACHE (0.53) ACHECES1MAOAAKR1B1ALDH1A1
SCHEMBL565750 0.82 ACHE (0.53) ACHECES1MAOAAKR1B1ALDH1A1
SCHEMBL31123671 0.72 ACHE (0.59) ACHECES1MAOAAKR1B1ALDH1A1
SCHEMBL86279 0.72 ACHE (0.59) ACHECES1MAOAAKR1B1ALDH1A1
SCHEMBL31510701 0.72 ACHE (0.59) ACHECES1MAOAAKR1B1ALDH1A1
SCHEMBL5845169 0.70 ACHE (1.00) ACHECES1MAOAAKR1B1ALDH1A1
SCHEMBL16138800 0.69 ACHE (0.50) ACHECES1MAOAAKR1B1ALDH1A1
SCHEMBL7195690 0.68 MIF (0.62) CES1MAOAALDH1A1BCHECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140296285-A1 PREPARATION AND APPLICATION OF THE NEW ANTIBACTERIAL AND ANTICANCER COMPOUNDS AND THEIR DERIVATIVES YANG GENGLIANG (CN) 2014-10-02 — — US disclosed
EP-2423213-B1 PREPARATION AND USE OF NOVEL ANTIBIOTIC, ANTICANCER COMPOUNDS AND DERIVATIVES THEREOF YANG GENGLIANG (CN) 2014-01-08 — — EP disclosed
EP-2423213-A1 PREPARATION AND USE OF NOVEL ANTIBIOTIC, ANTICANCER COMPOUNDS AND DERIVATIVES THEREOF Yang, Gengliang (CN) 2012-02-29 — — EP disclosed
US-20120035206-A1 PREPARATION AND APPLICATION OF NOVEL ANTIBACTERIAL AND ANTICANCER COMPOUNDS AND THEIR DERIVATIVES YANG, Gengliang (CN) 2012-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035206-A1 PREPARATION AND APPLICATION OF NOVEL ANTIBACTERIAL AND ANTICANCER COMPOUNDS AND THEIR DERIVATIVES MRPL21, NRDC, SOST ACHE 2202/4885CES1 3820/4885MAOA 4297/4885
US-20140296285-A1 PREPARATION AND APPLICATION OF THE NEW ANTIBACTERIAL AND ANTICANCER COMPOUNDS AND THEIR DERIVATIVES MRPL21, MCL1, MYC ACHE 1217/4885CES1 3694/4885MAOA 798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback